NCT03960151
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
Phase II Study of Rolapitant Plus Olanzapine, Palonosetron, and Dexamethasone in Patients With Germ Cell Tumors Undergoing 5-day Cisplatin-based Chemotherapy.
Costantine Albany·Phase 2·ClinicalTrials.gov·drugWithdrawn
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Germ Cell Tumor
- Drug/Device/Intervention
- Rolapitant
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Costantine Albany
- Funder
- Hoosier Cancer Research Network
Timeline & enrollment
- Phase
- Phase 2
- Start date
- May 01, 2018
- End date
- Mar 01, 2022
- Enrollment
- 0 participants
Primary outcome
Complete Response Rate
Summary
Phase II study of Rolapitant plus Olanzapine, Palonosetron, and Dexamethasone in patients
 with germ cell tumors undergoing 5-day Cisplatin-based chemotherapy
ICD-10 classifications
Malignant neoplasmsMalignant neoplasm: JejunumMalignant neoplasm: PrepuceMalignant neoplasm: Female genital organ, unspecifiedMalignant neoplasm: Vulva, unspecified
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT03960151
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT03960151 through Pure Global AI's free database. This Phase 2 trial is sponsored by Costantine Albany and is currently Withdrawn. The study focuses on Germ Cell Tumor. Target enrollment is 0 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.